CYP2D6 genotype and adverse events to risperidone in children and adolescents.

ABSTRACT: BACKGROUND:There are few and conflicting data on the role of cytochrome P450 2D6 (CYP2D6) polymorphisms in relation to risperidone adverse events (AEs) in children. This study assessed the association between CYP2D6 metabolizer status and risk for risperidone AEs in children. METHODS:Children ?18 years with at least 4 weeks of risperidone exposure were identified using BioVU, a de-identified DNA biobank linked to electronic health record data. The primary outcome of this study was AEs. After DNA sequencing, individuals were classified as CYP2D6 poor, intermediate, normal, or ultrarapid CYP2D6 metabolizers. RESULTS:For analysis, the 257 individuals were grouped as poor/intermediate metabolizers (n?=?33, 13%) and normal/ultrarapid metabolizers (n?=?224, 87%). AEs were more common in poor/intermediate vs. normal/ultrarapid metabolizers (15/33, 46% vs. 61/224, 27%, P?=?0.04). In multivariate analysis adjusting for age, sex, race, and initial dose, poor/intermediate metabolizers had increased AE risk (adjusted odds ratio 2.4, 95% confidence interval 1.1-5.1, P?=?0.03). CONCLUSION:Children with CYP2D6 poor or intermediate metabolizer phenotypes are at greater risk for risperidone AEs. Pre-prescription genotyping could identify this high-risk subset for an alternate therapy, risperidone dose reduction, and/or increased monitoring for AEs.

SUBMITTER: Oshikoya KA 

PROVIDER: S-EPMC6435416 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature